Researchers have found that tau, the protein best known for forming tangles inside dying neurons, can slip into the cell's energy-producing mitochondria and reverse the direction of their chemistry, a route to damage that operates separately from the tangles themselves.
The finding, published in the journal Neuron by a team led by Stanford Medicine scientists, describes a mechanism that had been suspected but never explained. Stanford's announcement noted that the long-observed connection between abnormal tau and mitochondrial problems had never been pinned down until now.
This is laboratory research describing biology. It is not an approved treatment, and it does not change anything about how Alzheimer's disease is currently diagnosed or managed.
Reversal Inside the Electron Transport Chain
Mitochondria convert calories from glucose or fat into usable energy through the electron transport chain, a multi-component assembly that passes electrons from one component to the next like a conveyor belt. The final step produces ATP, the energy currency every cell runs on.
Neurons are unusually dependent on this. They cannot store much energy, they fire constantly, and the brain consumes a disproportionate share of the body's fuel relative to its weight.
What the researchers found is that tau enters mitochondria only when phosphorylated, where it binds a component of the electron transport chain called NDUFS3, a subunit of complex I, and warps its shape. Electrons then drop off the conveyor belt and flow backward.
The consequence is not simply less energy. Reverse electron transport releases toxic ions that can damage proteins, DNA and other molecules, and it alters the chemistry of electron-carrying molecules that influence numerous enzymes, including some involved in aging. The paper reports it produces excess reactive oxygen species and reduces the NAD+ to NADH ratio.
There is also a feedback loop that the damage sustains on its own. Elevated reverse electron transport drives further tau hyperphosphorylation, which in turn drives more reversal.
Pathway Separate from Tangles
The detail that makes this finding interesting to drug developers is what it is not connected to.
Tau has two established roles in the disease story. In healthy neurons, it helps stabilize microtubules, the skeletal structures that maintain cell shape and support transport along the cell's length. In disease, abnormal tau twists into neurofibrillary tangles that accumulate inside neurons.
The newly described pathway is distinct from both. The authors frame it carefully: regulating reverse electron transport appears to be a previously unrecognized normal function of tau that becomes pathological in disease, rather than a purely destructive activity. Russell Swerdlow, a neurologist at the University of Kansas Medical Center who was not involved in the work, noted that because the phenomenon appeared across every species studied, it likely serves an evolutionary purpose and may help neurons survive temporary stress.
The work was tested in flies, mice and human stem-cell neurons, and depleting tau eliminated stress-induced reversal in all three, conferring resistance to stress.
Experimental Compound and Its Backing
The translational element is stated with its disclosure attached.
The researchers gave mice an experimental compound called CPT, which binds NDUFS3 and crowds out phosphorylated tau, preventing the reversal. Treated animals performed better on cognitive tests and showed less inflammation and fewer signs of neurodegeneration. STAT reported that blocking it improved learning and memory in animals across both flies and mice.
CPT is being tested in animals by Cerepeut, a biotechnology company co-founded by the study's senior author, Bingwei Lu. He has said he hopes to begin human trials within two years. That is a founder's projection rather than a scheduled milestone, and readers should weigh the financial interest alongside the finding.
The limitation belongs stated plainly. Demonstrating that a molecular interaction damages cells, and that blocking it helps mice, is a long way from demonstrating that it preserves memory in people. The history of Alzheimer's drug development is largely a history of mechanisms that did not translate.
Distance Between Mechanism and Medicine
Nobody should expect an available treatment from this in the near term. Even on the optimistic timeline the researchers describe, a compound must be shown safe, shown to reach the brain, and then tested across years of trials measuring cognitive outcomes. Most candidates fail somewhere along that path.
There is also a specific complication the authors' own framing raises. If regulating reverse electron transport is a normal function of tau, and recent research has found tau serves necessary roles in memory formation, then broadly suppressing the protein carries risk. A pathway that could be targeted without eliminating tau's healthy roles would be more attractive, and that is part of why a discrete protein interaction attracts interest.
For families living with Alzheimer's disease now, the useful actions are unchanged and unrelated to this research. Anyone noticing memory changes that interfere with daily activities should seek evaluation rather than attributing them to age, because several treatable conditions mimic dementia, including thyroid disorders, vitamin B12 deficiency, medication effects, sleep apnea and depression.
People already diagnosed can ask their clinician about eligibility for approved therapies, about clinical trials at academic centers, and about caregiver support services, which are consistently underused. No one should purchase supplements or products marketed as targeting tau or mitochondrial health on the basis of a laboratory finding.
Sudden confusion, a rapid change in alertness, or an abrupt decline over days rather than months is not typical of Alzheimer's disease and warrants urgent medical evaluation.
The bottom line: the newest finding is that phosphorylated tau binds a mitochondrial enzyme and reverses electron flow, producing oxidative stress through a route distinct from tangles; an experimental compound blocked the effect in animals; the work is laboratory-based with a disclosed commercial interest; and it changes no aspect of current diagnosis or treatment.
Key Questions Answered
What did the study find? Phosphorylated tau enters mitochondria and binds NDUFS3, a subunit of complex I, reversing the direction of electron flow and generating reactive oxygen species, cellular stress and inflammation.
What models were used? Flies, mice, and human induced pluripotent stem cell-derived neurons. Depleting tau eliminated stress-induced reversal in all three.
Is this the same as tau tangles? No. The researchers describe this pathway as distinct from neurofibrillary tangle formation and microtubule instability, and frame it as a normal tau function that becomes pathological.
Was a drug tested? An experimental compound called CPT blocked the tau-NDUFS3 interaction and improved cognitive performance in animals. It has not been tested in people.
Are there financial interests to note? Yes. CPT is being developed by Cerepeut, a company co-founded by the study's senior author, who has said he hopes to start human trials within two years.
Does this mean a new Alzheimer's drug is coming? Not necessarily. This is animal and cell research. Translating a molecular interaction into an approved therapy takes years, and most candidates fail.
What symptoms warrant evaluation? Memory changes interfering with daily activities deserve assessment, since several treatable conditions mimic dementia. Sudden confusion or rapid decline over days requires urgent care.
